2.50
Hdl Handle:
http://hdl.handle.net/10541/94847
Title:
VS38 immunostaining in neuroendocrine tumours.
Authors:
Banerjee, Saumitra S; Shanks, Jonathan H; Hasleton, Philip S
Abstract:
VS38 was originally described as a marker of neoplastic and non-neoplastic plasma cells. We recently described its immunoreactivity with melanocytic lesion. The aim of the present study was to investigate the reactivity of VS38 with various neuroendocrine tumours. Using paraffin sections of routinely processed archival tissue we found that 72% of 50 neuroendocrine tumours tested showed immunohistochemical positivity for VS38. A wide spectrum of neuroendocrine tumours were positive. Use of a panel of markers and awareness of the lack of specificity of VS38 will avoid misdiagnosis, particularly when neuroendocrine tumours and other lesions which react immunohistochemically with this antibody are located at unusual sites and exhibit plasmacytoid features.
Affiliation:
Department of Histopathology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
VS38 immunostaining in neuroendocrine tumours. 1997, 30 (3):256-9 Histopathology
Journal:
Histopathology
Issue Date:
Mar-1997
URI:
http://hdl.handle.net/10541/94847
DOI:
10.1046/j.1365-2559.1997.d01-599.x
PubMed ID:
9088955
Type:
Article
Language:
en
ISSN:
0309-0167
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBanerjee, Saumitra Sen
dc.contributor.authorShanks, Jonathan Hen
dc.contributor.authorHasleton, Philip Sen
dc.date.accessioned2010-03-24T14:05:14Z-
dc.date.available2010-03-24T14:05:14Z-
dc.date.issued1997-03-
dc.identifier.citationVS38 immunostaining in neuroendocrine tumours. 1997, 30 (3):256-9 Histopathologyen
dc.identifier.issn0309-0167-
dc.identifier.pmid9088955-
dc.identifier.doi10.1046/j.1365-2559.1997.d01-599.x-
dc.identifier.urihttp://hdl.handle.net/10541/94847-
dc.description.abstractVS38 was originally described as a marker of neoplastic and non-neoplastic plasma cells. We recently described its immunoreactivity with melanocytic lesion. The aim of the present study was to investigate the reactivity of VS38 with various neuroendocrine tumours. Using paraffin sections of routinely processed archival tissue we found that 72% of 50 neuroendocrine tumours tested showed immunohistochemical positivity for VS38. A wide spectrum of neuroendocrine tumours were positive. Use of a panel of markers and awareness of the lack of specificity of VS38 will avoid misdiagnosis, particularly when neuroendocrine tumours and other lesions which react immunohistochemically with this antibody are located at unusual sites and exhibit plasmacytoid features.en
dc.language.isoenen
dc.subjectCancer Antibodiesen
dc.subjectCancer Antigensen
dc.subjectNeuroendocrine Tumoursen
dc.subjectBiological Tumour Markersen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntibodies, Neoplasm-
dc.subject.meshAntigens, Neoplasm-
dc.subject.meshHumans-
dc.subject.meshNeuroendocrine Tumors-
dc.subject.meshPlasma Cells-
dc.subject.meshPlasmacytoma-
dc.subject.meshTumor Markers, Biological-
dc.titleVS38 immunostaining in neuroendocrine tumours.en
dc.typeArticleen
dc.contributor.departmentDepartment of Histopathology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalHistopathologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.